Welcome to our dedicated page for Genenta Science Spa SEC filings (Ticker: GNTA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Genenta Science S.p.A. (NASDAQ: GNTA) SEC filings page on Stock Titan brings together the company’s regulatory documents as filed with the U.S. Securities and Exchange Commission. As a foreign private issuer and clinical-stage immuno-oncology company, Genenta reports key information about its Temferon™ development programs, financing activities, and governance through Form 6-K and related filings.
In these filings, investors can find unaudited consolidated financial statements and Management’s Discussion and Analysis of Financial Condition and Results of Operations, which outline Genenta’s cash resources, operating expenses, and funding runway in relation to its solid tumor clinical programs. Other 6-Ks describe registered direct offerings of American Depositary Shares under a shelf registration statement on Form F-3, including purchase agreements, placement agency agreements, and use-of-proceeds language.
Genenta also uses SEC filings to document a Mandatory Convertible Bond financing with ENEA Tech and Biomedical, amendments to its by-laws, changes in the size and composition of its Board of Directors, and executive leadership transitions such as the appointment or resignation of a Chief Medical Officer. Shareholder meeting notices and outcomes, including approvals of statutory financial statements and director appointments, are similarly detailed in these reports.
Through Stock Titan, users can access Genenta’s 6-Ks, registration statements, prospectus supplements, and related exhibits as they are made available on EDGAR, along with AI-powered summaries that explain the practical meaning of each document. This includes highlighting where Genenta discusses its Temferon clinical trials in glioblastoma multiforme and metastatic renal cell carcinoma, capital structure changes, and material agreements with manufacturing partners. For those monitoring insider holdings, the SEC database also provides ownership and transaction reports that complement the company’s own ownership updates.
Use this page to quickly review GNTA’s latest SEC filings, compare new disclosures with prior reports, and understand how regulatory documents reflect the evolution of Genenta’s immuno-oncology platform and corporate strategy.
Genenta Science S.p.A. reported that its CMO & Head of Development, Francesco Galimi, received a grant of stock options covering 20,000 American Depositary Shares. The options have an exercise price of $0.63 per share and expire on December 31, 2035.
The options vest in equal monthly installments over one year beginning March 30, 2026. Following this grant, Galimi holds stock options for 20,000 ADS directly, reflecting a compensation-related award rather than an open-market transaction.
Genenta Science S.p.A. director Giacomoantonio Paracchi reported a compensation-related grant of stock options. On March 30, 2026, he was awarded options covering 20,000 American Depositary Shares at an exercise price of $0.63 per share, expiring on December 31, 2035.
The options vest in equal monthly installments over one year beginning March 30, 2026, aligning the award with ongoing service. Following this grant, Paracchi holds 20,000 stock options directly.
Genenta Science S.p.A. director Sharei Armon received a grant of stock options for 20,000 American Depositary Shares. The options have an exercise price of $0.63 per share and expire on December 31, 2035. They vest in equal monthly installments over one year beginning March 30, 2026.
Genenta Science S.p.A. director Mutti Miguel Maria received a grant of stock options covering 20,000 American Depositary Shares. The options were granted at no cost, with an exercise price of $0.63 per share and an expiration date of December 31, 2035.
The options vest in equal monthly installments over one year beginning March 30, 2026, aligning the director’s compensation with longer-term company performance. Following this grant, the director holds 20,000 stock options directly, with no open-market share purchases or sales reported in this filing.
Genenta Science S.p.A. reported that Chief Financial Officer Richard B. Slansky received a grant of stock options covering 80,000 American Depositary Shares. The options have an exercise price of $0.63 per share and expire on December 31, 2035.
The award was granted at no cost and is a compensation-related acquisition, not an open-market purchase. According to the footnote, the options vest in equal monthly installments over three years beginning March 30, 2026, and all 80,000 options were reported as held directly following the transaction.
Genenta Science S.p.A. files its Form 20-F annual report for the year ended December 31, 2025, detailing its clinical-stage gene therapy business and strategic shift toward industrial consolidation in national security–related sectors.
The company reports 23,432,183 ordinary shares outstanding as of December 31, 2025 and cash, cash equivalents and marketable securities of about €28.1 million. It remains loss-making, with 2025 net loss of roughly €6.5 million and an accumulated deficit of about €62.6 million.
Genenta highlights substantial financing flexibility, including a $100.0 million shelf registration with approximately $86.0 million remaining and an at-the-market facility with about $26.4 million of capacity left. Extensive risk disclosures emphasize ongoing funding needs, clinical and regulatory uncertainties for Temferon, and execution risks in its planned transformation into a “next-generation strategic industrial consolidator.”
Genenta Science is pursuing a binding offer to acquire up to 51% of Sòphia High Tech, an Italian aerospace and defense manufacturer, by funding EUR 6.0 million through two reserved capital increases and payments to the founders, with the second tranche tied to EBITDA milestones.
The offer includes an initial 30% stake, a performance-based earnout and a 90-day exclusivity period, and is subject to confirmatory due diligence, required government approvals and definitive documentation. Genenta is evolving into Saentra Forge, a strategic consolidator in biotech, defense, aerospace and Italian national-security sectors, with Sòphia HT described as already profitable and projecting EBITDA growth.
Genenta Science S.p.A. director Giacomoantonio Paracchi has filed an initial Form 3 ownership report indicating that he does not currently own any ordinary shares, American Depositary Shares, or derivative securities of the company. Each American Depositary Share represents one ordinary share with no par value.
Genenta Science S.p.A. has cancelled its previously scheduled Extraordinary Shareholders’ Meeting of March 25–26, 2026, which was convened to approve a change of the company’s name to Saentra Forge S.p.A. and a related Nasdaq ticker change.
The board decided to revoke the meeting call after concluding that the Genenta name still carries strong recognition, value, and market presence built over more than a decade. The company notes that the already approved extension of its corporate purpose, linked to Italy’s Golden Power legislation, remains in an early development phase, and the Saentra Forge branding requires further positioning before any future rebrand.
Genenta Science S.p.A. director Sharei Armon has reported initial holdings consisting solely of stock options linked to American Depositary Shares (ADSs). These include options over 20,163 ADSs at an exercise price of $3.0800 per share, which became fully vested and exercisable on July 1, 2024.
Armon also holds options over 20,000 ADSs at an exercise price of $4.3600, vesting in equal monthly installments over one year beginning June 4, 2025, and options over 10,000 ADSs at $1.4800, vesting monthly over one year beginning December 18, 2025. Each ADS represents one ordinary share of Genenta.